ResMed Inc. introduced a new platform of portable, lightweight and user-friendly life support ventilators in some European and Asia-Pacific markets, the company said.
ResMed hopes to have Astral life support ventilators available in the U.S. later this year, pending clearance from the Food and Drug Administration.
San Diego-based ResMed (NYSE: RMD) said its Astral life support ventilators, Astral 100 and Astral 150, offer mobility and ease of use for patients suffering from neuromuscular disease, COPD, and other adult and childhood breathing disorders. The products feature large touchscreen displays and easy-to-navigate graphic user interfaces that can be accessed without removing the devices from their mobility bags, the company said.
In April, ResMed reported net income of $90 million for the quarter ended March 31.
The company has made moves to pursue opportunities in emerging markets.
ResMed is a medical device biotech focusing on sleep-disordered breathing and the management and treatment of other breathing disorders.